• Je něco špatně v tomto záznamu ?

The effectiveness of second- and-third-line biologics in perianal Crohn's disease-a multicenter propensity score-matched study

U. Shani, M. State, RB. Mateescu, AM. Davidoiu, L. Negreanu, I. Silva, F. Magro, CW. Lees, N. Plevris, X. Roblin, S. Castellet-Farrús, Y. Gonzalez Lama, S. Wang, C. Abad, N. Imperatore, M. Lukas, G. Vojtechova, O. Ukashi, S. Ben-Horin, S. Nancey,...

. 2025 ; 19 (6) : . [pub] 20250604

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015365

BACKGROUND AND AIMS: Anti-tumor necrosis factor-α inhibitors (anti-TNFs) are the established treatment for perianal Crohn's disease (pCD), but relapse and non-response are common. Data on second- and third-line biologics are limited. We present the first direct comparison of second- and third-line biologics in pCD patients with active perianal disease previously treated with first-line anti-TNFs. METHODS: A multicenter retrospective cohort study included adult patients with pCD who failed first-line anti-TNF. The primary outcome was clinical perianal response, with secondary outcomes of radiological response (magnetic resonance imaging or transrectal ultrasound) and healing, and clinical remission. Propensity score matching (PSM) was used to adjust for baseline differences. RESULTS: A total of 486 pCD patients from 23 IBD centers were included, with 333/486 (68.5%) and 216/263 (82.1%) matched by PSM in the second and third-line treatment groups, respectively. In the second-line group, 62/78 (79.5%) of ustekinumab (UST)-treated patients achieved clinical perianal response, compared to 46/78 (58.9%) with vedolizumab (VDZ) (OR 4.47, 95% CI, 1.94-10.28, P < .001) and 38/78 (48.7%) with anti-TNFs (OR 5.29, 95% CI, 2.39-11.71, P < .001). In the third-line group, 38/49 (77.6%) of UST-treated patients achieved clinical perianal response, compared to 29/49 (59.2%) with VDZ (OR 9.96, 95% CI, 2.6-38.4, P < .001) and 27/49 (55.1%) with anti-TNFs (OR 12.03, 95% CI, 2.99-48.47, P < .001). UST-treated patients also had higher radiological response rates than VDZ (OR 3.28, 95% CI, 1.07-10.07, P = .038). CONCLUSION: In pCD patients failing anti-TNFs as first-line treatment, ustekinumab may be more effective than vedolizumab or another anti-TNF as second or third-line therapy.

2nd Department of Internal Medicine Gastroenterology and Geriatrics University Hospital Olomouc Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic

CEMAD IBD UNIT Unità Operativa Complessa di Medicina Interna e Gastroenterologia Dipartimento di Scienze Mediche e Chirurgiche Fondazione Policlinico Universitario A Gemelli IRCCS Rome Italy

Center for Gastroenterology Department of Internal Medicine University of Szeged Szeged Hungary

Centre for Genomic and Experimental Medicine Institute of Genetics and Cancer University of Edinburgh Edinburgh United Kingdom

Clinical and Research Center for Inflammatory Bowel Disease ISCARE and 1st Faculty of Medicine Charles University Prague Czech Republic

Clinical Pharmacology Unit São João University Hospital Center Porto Portugal

Department of Gastroenterology and Hepatology Ghent University Hospital Ghent Belgium

Department of Gastroenterology Dietetics and Internal Diseases Poznan University of Medical Sciences Poznan Poland

Department of Gastroenterology Hepatology and Clinical Oncology Centre of Postgraduate Medical Education Warsaw Poland

Department of Gastroenterology Hepatology and Nutrition University Hospital Zagreb Zagreb Croatia

Department of Gastroenterology Hospital de Bellvitge L'Hospitalet Spain

Department of Gastroenterology Lyon Sud Hospital Hospices Civils de Lyon and INSERM U1111 University Claude Bernard Lyon 1 Lyon France

Department of Gastroenterology Sheba Medical Center Tel Hashomer Ramat Gan Israel

Department of Gastroenterology Venizeleio General Hospital Heraklion Greece

Department of IBD and Wolfson Unit for Endoscopy St Mark's National Bowel Hospital London United Kingdom

Department of Internal Medicine B Sheba Medical Center Tel Hashomer Ramat Gan Israel

Department of Oncological Gastroenterology The Maria Sklodowska Curie National Research Institute of Oncology Warsaw Poland

Digestive Diseases Centre Hospital AGEL Vitkovice Ostrava Czech Republic

Dipartimento Universitario di Medicina e Chirurgia Traslazionale Università Cattolica del Sacro Cuore Rome Italy

Division of Gastroenterology Department of Medicine University of Alberta Edmonton Alberta Canada

Edinburgh IBD Unit Western General Hospital Edinburgh United Kingdom

Gastroenterology and Endoscopy Unit Santa Maria delle Grazie Hospital Pozzuoli Naples Italy

Gastroenterology Department Colentina Clinical Hospital Carol Davila University of Medicine and Pharmacy Bucharest Romania

Gastroenterology Department Hospital Clínico Universitario de Santiago de Compostela Santiago Spain

Gastroenterology Department University Hospital Carol Davila University of Medicine and Pharmacy Bucharest Romania

Gastroenterology Unit Azienda Ospedale Università di Padova Padua Italy

Inflammatory Bowel Disease Unit Department of Gastroenterology and Hepatology Hospital Universitario Puerta de Hierro Majadahonda Madrid Spain

School of Medicine University of Zagreb Zagreb Croatia

Service de Gastrologie Entérologie Hépatologie CHU de Saint Etienne Saint Etienne France

University Hospital São João Porto Portugal

UOS Gastroenterologia Ospedale Isola Tiberina Gemelli Isola 00186 Rome Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015365
003      
CZ-PrNML
005      
20250731090931.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ecco-jcc/jjaf099 $2 doi
035    __
$a (PubMed)40490896
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Shani, Uria $u Department of Internal Medicine B, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel $1 https://orcid.org/0000000314361133
245    14
$a The effectiveness of second- and-third-line biologics in perianal Crohn's disease-a multicenter propensity score-matched study / $c U. Shani, M. State, RB. Mateescu, AM. Davidoiu, L. Negreanu, I. Silva, F. Magro, CW. Lees, N. Plevris, X. Roblin, S. Castellet-Farrús, Y. Gonzalez Lama, S. Wang, C. Abad, N. Imperatore, M. Lukas, G. Vojtechova, O. Ukashi, S. Ben-Horin, S. Nancey, E. Savarino, K. Stawczyk-Eder, P. Eder, A. Toskas, N. Kamperidis, N. Arebi, B. Farkas, K. Farkas, B. Pipek, P. Falt, K. Karmiris, P. Nikolaou, Z. Krznaric, M. Brinar, F. Hoentjen, L. van Lierop, M. Barreiro-de Acosta, M. Zaborowska, E. Zagorowicz, D. Pugliese, G. Cuccia, M. Truyens, U. Kopylov
520    9_
$a BACKGROUND AND AIMS: Anti-tumor necrosis factor-α inhibitors (anti-TNFs) are the established treatment for perianal Crohn's disease (pCD), but relapse and non-response are common. Data on second- and third-line biologics are limited. We present the first direct comparison of second- and third-line biologics in pCD patients with active perianal disease previously treated with first-line anti-TNFs. METHODS: A multicenter retrospective cohort study included adult patients with pCD who failed first-line anti-TNF. The primary outcome was clinical perianal response, with secondary outcomes of radiological response (magnetic resonance imaging or transrectal ultrasound) and healing, and clinical remission. Propensity score matching (PSM) was used to adjust for baseline differences. RESULTS: A total of 486 pCD patients from 23 IBD centers were included, with 333/486 (68.5%) and 216/263 (82.1%) matched by PSM in the second and third-line treatment groups, respectively. In the second-line group, 62/78 (79.5%) of ustekinumab (UST)-treated patients achieved clinical perianal response, compared to 46/78 (58.9%) with vedolizumab (VDZ) (OR 4.47, 95% CI, 1.94-10.28, P < .001) and 38/78 (48.7%) with anti-TNFs (OR 5.29, 95% CI, 2.39-11.71, P < .001). In the third-line group, 38/49 (77.6%) of UST-treated patients achieved clinical perianal response, compared to 29/49 (59.2%) with VDZ (OR 9.96, 95% CI, 2.6-38.4, P < .001) and 27/49 (55.1%) with anti-TNFs (OR 12.03, 95% CI, 2.99-48.47, P < .001). UST-treated patients also had higher radiological response rates than VDZ (OR 3.28, 95% CI, 1.07-10.07, P = .038). CONCLUSION: In pCD patients failing anti-TNFs as first-line treatment, ustekinumab may be more effective than vedolizumab or another anti-TNF as second or third-line therapy.
650    _2
$a lidé $7 D006801
650    12
$a Crohnova nemoc $x farmakoterapie $x diagnostické zobrazování $7 D003424
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a tendenční skóre $7 D057216
650    _2
$a dospělí $7 D000328
650    _2
$a retrospektivní studie $7 D012189
650    12
$a ustekinumab $x terapeutické užití $7 D000069549
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    12
$a biologické přípravky $x terapeutické užití $7 D001688
650    _2
$a lidé středního věku $7 D008875
650    _2
$a výsledek terapie $7 D016896
650    12
$a nemoci anu $x farmakoterapie $7 D001004
650    12
$a gastrointestinální látky $x terapeutické užití $7 D005765
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a inhibitory TNF $x terapeutické užití $7 D000079424
650    _2
$a indukce remise $7 D012074
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a State, Monica $u Gastroenterology Department, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Mateescu, Radu Bogdan $u Gastroenterology Department, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Davidoiu, Ana-Maria $u Gastroenterology Department, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Negreanu, Lucian $u Gastroenterology Department, University Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
700    1_
$a Silva, Isabel $u Clinical Pharmacology Unit, São João University Hospital Center, Porto, Portugal
700    1_
$a Magro, Fernando $u University Hospital São João, Porto, Portugal
700    1_
$a Lees, Charlie W $u Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom $u Edinburgh IBD Unit, Western General Hospital, Edinburgh, United Kingdom
700    1_
$a Plevris, Nikolas $u Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom $u Edinburgh IBD Unit, Western General Hospital, Edinburgh, United Kingdom $1 https://orcid.org/0000000232298759
700    1_
$a Roblin, Xavier $u Service de Gastrologie-Entérologie-Hépatologie, CHU de Saint-Etienne, Saint-Etienne, France
700    1_
$a Castellet-Farrús, Sílvia $u Department of Gastroenterology, Hospital de Bellvitge, L'Hospitalet, Spain
700    1_
$a Gonzalez Lama, Yago $u Inflammatory Bowel Disease Unit, Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
700    1_
$a Wang, Shanshan $u Inflammatory Bowel Disease Unit, Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain $1 https://orcid.org/0009000677650919
700    1_
$a Abad, Carolina $u Inflammatory Bowel Disease Unit, Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
700    1_
$a Imperatore, Nicola $u Gastroenterology and Endoscopy Unit, Santa Maria delle Grazie Hospital, Pozzuoli, Naples, Italy
700    1_
$a Lukas, Milan $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000214633840 $7 jn19990202012
700    1_
$a Vojtechova, Gabriela $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Ukashi, Offir $u Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel $1 https://orcid.org/0000000286016550
700    1_
$a Ben-Horin, Shomron $u Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
700    1_
$a Nancey, Stephane $u Department of Gastroenterology, Lyon-Sud Hospital, Hospices Civils de Lyon and INSERM U1111, University Claude Bernard Lyon 1, Lyon, France
700    1_
$a Savarino, Edoardo $u Gastroenterology Unit, Azienda Ospedale Università di Padova, Padua, Italy
700    1_
$a Stawczyk-Eder, Kamila $u Department of Gastroenterology, Dietetics, and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland
700    1_
$a Eder, Piotr $u Department of Gastroenterology, Dietetics, and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland
700    1_
$a Toskas, Alexandros $u Department of IBD and Wolfson Unit for Endoscopy, St Mark's National Bowel Hospital, London, United Kingdom
700    1_
$a Kamperidis, Nikolaos $u Department of IBD and Wolfson Unit for Endoscopy, St Mark's National Bowel Hospital, London, United Kingdom
700    1_
$a Arebi, Naila $u Department of IBD and Wolfson Unit for Endoscopy, St Mark's National Bowel Hospital, London, United Kingdom
700    1_
$a Farkas, Bernadett $u Center for Gastroenterology, Department of Internal Medicine, University of Szeged, Szeged, Hungary $1 https://orcid.org/0009000788160138
700    1_
$a Farkas, Klaudia $u Center for Gastroenterology, Department of Internal Medicine, University of Szeged, Szeged, Hungary $1 https://orcid.org/000000030599182X
700    1_
$a Pipek, Barbora $u Digestive Diseases Centre, Hospital AGEL Vitkovice, Ostrava, Czech Republic $u Second Department of Internal Medicine, Gastroenterology and Geriatrics, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Falt, Premysl $u Second Department of Internal Medicine, Gastroenterology and Geriatrics, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Karmiris, Konstantinos $u Department of Gastroenterology, Venizeleio General Hospital, Heraklion, Greece $1 https://orcid.org/0000000335523074
700    1_
$a Nikolaou, Pinelopi $u Department of Gastroenterology, Venizeleio General Hospital, Heraklion, Greece
700    1_
$a Krznaric, Zeljko $u School of Medicine, University of Zagreb, Zagreb, Croatia $u Department of Gastroenterology, Hepatology and Nutrition, University Hospital Zagreb, Zagreb, Croatia
700    1_
$a Brinar, Marko $u School of Medicine, University of Zagreb, Zagreb, Croatia $u Department of Gastroenterology, Hepatology and Nutrition, University Hospital Zagreb, Zagreb, Croatia
700    1_
$a Hoentjen, Frank $u Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
700    1_
$a van Lierop, Lisa $u Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
700    1_
$a Barreiro-de Acosta, Manuel $u Gastroenterology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago, Spain $1 https://orcid.org/0000000159151477
700    1_
$a Zaborowska, Marta $u Department of Oncological Gastroenterology, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
700    1_
$a Zagorowicz, Edyta $u Department of Oncological Gastroenterology, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland $u Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland
700    1_
$a Pugliese, Daniela $u CEMAD, IBD UNIT, Unità Operativa Complessa di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy $u Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy $u UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, 00186 Rome, Italy
700    1_
$a Cuccia, Giuseppe $u Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy
700    1_
$a Truyens, Marie $u Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
700    1_
$a Kopylov, Uri $u Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel $1 https://orcid.org/0000000271560588
773    0_
$w MED00166945 $t Journal of Crohn's and colitis $x 1876-4479 $g Roč. 19, č. 6 (2025)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40490896 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090925 $b ABA008
999    __
$a ok $b bmc $g 2366294 $s 1252490
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 19 $c 6 $e 20250604 $i 1876-4479 $m Journal of Crohn's and colitis $n J Crohns Colitis $x MED00166945
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace